NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
about
PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.Role of HGF/MET axis in resistance of lung cancer to contemporary management.Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant diseaseFusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesEvidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.Targeted inhibition in tumors with ALK dependency.Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Kinase overexpressing cancers responsive to drug withdrawal.ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
P2860
Q34489388-739DFA63-CE49-4524-9C88-FBDDF5A53BE0Q35200337-1C7DA824-BF01-4C9D-B7C4-F9586A1AB288Q35863674-6A23B95A-E7C9-4138-8C79-19564421989DQ36082481-5A93566F-759A-4B4D-BEBF-1AB38792005DQ36602853-A15B2D66-B5D5-46EA-B607-BEC6ED8C41B0Q38870250-659043AA-C2AD-4503-9CD4-6410244BF254Q38874456-487B10CB-C2CF-4A49-9622-2333DF2DC13BQ38956321-79E579E5-A134-4373-A658-DC7C862C99E6Q38956444-931032E4-4D06-43DA-B170-FE440237FD47Q38962008-465480DB-02D1-462A-A2A9-47E050E9F67DQ41133791-FCBEA19D-AD7A-454F-A3F2-04B02152C5E6Q42697768-F9BC6EC0-18BB-4F34-885B-DB80506A903BQ43184268-C18D4EB1-2120-4F3D-9695-0D20EB2E55B2Q54358602-2C890996-3B7E-45D6-9121-ADC59E6E48CA
P2860
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@en
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@nl
type
label
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@en
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@nl
prefLabel
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@en
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.
@nl
P2093
P2860
P356
P1476
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
@en
P2093
Joel D Pearson
Julinor T C Bacani
Raymond Lai
Robert J Ingham
P2860
P304
P356
10.1155/2012/123253
P577
2012-07-18T00:00:00Z